Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Rachel ScheckLaboratory of Translational Immunology of Viral Infections, Department of Infectious Diseases and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.ORCID http://orcid.org/0009-0004-8354-9943
Naomi PerkinsLaboratory of Translational Immunology of Viral Infections, Department of Infectious Diseases and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany.
R Brad Jones *Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, USA. rbjones@med.cornell.edu.ORCID http://orcid.org/0000-0003-4470-1231
Christian Gaebler *Laboratory of Translational Immunology of Viral Infections, Department of Infectious Diseases and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Berlin Institute of Health, Berlin, Germany. christian.gaebler@charite.de.ORCID http://orcid.org/0000-0001-7295-8128
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
INSPIRE: Innovative Strategies for Personalized Immunotherapies and Reservoir EradicationUM1AI191237 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2025 to 2026
$5.9M
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational ApproachR01AI176601 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI R. Brad Jones, Neville Sanjana · 2023 to 2026
$3.3M
Mechanisms of CTL Resistance in HIV ReservoirsR01AI170245 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2022 to 2025
$3.0M
Phylodynamic mechanisms of HIV reservoir seeding and maintenanceR01AI186721 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Daniel Reeves · 2024 to 2026
$2.6M
Defining and then Maximizing the Footprint of CTL Selection on HIV Integration Site Landscapes to Optimize Cure StrategiesR37AI181626 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Frederic D Bushman, R. Brad Jones · 2024 to 2026
$2.5M
Early interventions at ART initiation to reduce the HIV-1 reservoir and enhance adaptive immune responsesR01AI184285 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Michael R Betts, Brad R Jones · 2024 to 2026
$2.1M
Simulating persistence and elimination of the HIV reservoirK25AI155224 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI REEVES, DANIEL · 2020 to 2024
$581k
Deutsche Forschungsgemeinschaft (German Research Foundation) Walter-Benjamin Stipendium, 549131684EC | EU Framework Programme for Research and Innovation H2020 | H2020 Excellent Science (H2020 Priority Excellent Science) 101162138NIAID NIH HHS K25 AI155224NIAID NIH HHS R01 AI170245NIAID NIH HHS R01 AI176601NIAID NIH HHS R01 AI184285NIAID NIH HHS R01 AI186721NIAID NIH HHS R37 AI181626NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI164565NIAID NIH HHS UM1 AI191237U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01 AI186721-01U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) UM1 AI068634, UM1 AI068636, UM1 AI106701
6 · The paper itself
Abstract
Precise and scalable quantification of the intact HIV reservoir is critical for advancing curative strategies. Current reservoir assays, such as the intact proviral DNA assay (IPDA), are limited by quantification failures or misclassification of defective proviruses due to HIV sequence heterogeneity. Q4ddPCR is a modular, droplet digital PCR simultaneously targeting four conserved regions in the HIV genome to improve specificity, reduce quantification gaps, and provide multi-layered readouts. It comprises two configurations: one fully based on Q4PCR primer/probes and one combining IPDA with gag and pol primer/probes from Q4PCR. We benchmark Q4ddPCR against 3650 near full-length proviral sequences from 13 virally suppressed people with HIV (PWH) generated by Q4PCR. Q4ddPCR closely matches sequence-confirmed reservoir measurements, and multi-probe readouts reveal clonal reservoir dynamics not detectable by IPDA. Q4ddPCR enables intact reservoir quantification in 95% of samples across four independent cohorts and in 16 PWH, strongly correlates with viral outgrowth. In longitudinal samples from 42 participants over the first 4.5 years on antiretroviral therapy (ART), Q4ddPCR reports lower proviral frequencies and a steeper decline in intact proviral DNA compared to IPDA. Collectively, our findings confirm key predictions from mathematical modeling, demonstrating that multi-target assays improve specificity and more accurately capture intact reservoir dynamics.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling. · full record | OpenQuestion